Petia Shipkova

Bristol-Myers Squibb (United States)

Papers

1

Total Citations

37

H-Index

1

About

Petia Shipkova is a distinguished analytical chemist whose work has significantly advanced the field of drug metabolism and pharmaceutical profiling. Her primary research focuses on developing high-throughput mass spectrometry and liquid chromatography methodologies to accelerate the assessment of drug candidate properties. Shipkova’s most notable contribution is the creation of the MetFast assay, an automated high-throughput process that evaluates the in vitro metabolic stability of potential drug candidates. This innovation, detailed in her highly cited 2007 paper (37 citations), enables rapid screening of cytochrome P450-mediated first-pass metabolism, a critical factor in drug development. By streamlining the identification of stable, viable compounds early in the pipeline, her work has helped reduce attrition rates and expedite the discovery of safer, more effective therapeutics. Shipkova’s research sits at the intersection of analytical chemistry and pharmaceutical science, providing essential tools for profiling drug candidates. Her contributions have been instrumental in enhancing the efficiency of preclinical drug development, making her a key figure in the evolution of modern pharmaceutical analysis and metabolic stability assessment.

Research Focus

Key Achievements

1
H-Index
1
Papers
37
Total Citations
37
Avg Citations/Paper
🏆 Most Cited Paper
An Automated High Throughput Liquid Chromatography–Mass Spectrometry Process to Assess the Metabolic Stability of Drug Candidates
37 citations · 2007
📈 Most Prolific Year: 2007 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: Bristol-Myers Squibb (United States)

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago